Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
about
EZH2 methyltransferase and H3K27 methylation in breast cancerPrognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysisDevelopmental therapeutics for inflammatory breast cancer: Biology and translational directionsPotential epigenetic mechanism(s) associated with the persistence of psychoneurological symptoms in women receiving chemotherapy for breast cancer: a hypothesisEnhancer of zeste homolog 2 induces pulmonary artery smooth muscle cell proliferation.Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer.UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells.Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical modelLoss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysisPrognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma.Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.Histone demethylase KDM6B promotes epithelial-mesenchymal transition.EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.MicroRNA-298 inhibits malignant phenotypes of epithelial ovarian cancer by regulating the expression of EZH2.Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression.Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion.Epigenetic and genetic alterations-based molecular classification of head and neck cancer.EZH2 is overexpressed in laryngeal squamous cell carcinoma and enhances the stem-like properties of AMC-HN-8 cells.Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.Proximal and distal regulation of the HYAL1 gene cluster by the estrogen receptor α in breast cancer cells.Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.MUC1-C activates EZH2 expression and function in human cancer cells.Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses' Health Study.MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.EZH2 regulates spinal neuroinflammation in rats with neuropathic pain.Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.
P2860
Q24633788-E9C243A3-82EE-432D-96E4-62E1213D17F6Q27853296-0D3E29DB-3FCF-46AB-B31A-7228D5BD008CQ28075322-8B536990-620A-4933-A3BA-3DBD79BCC25BQ28393302-E3167A64-EE49-4037-8A83-EAB1A130DED7Q34291184-0C8CF74A-8CD8-4C70-8410-587DD56DA153Q34343963-EBF9E150-1C07-4652-9353-1AA5ACF70BE7Q34401922-FC3721B6-9A6F-439A-AECF-1C0DDD09CE75Q35313206-33DF354F-1B2C-495E-82AF-448DF05C8849Q35568071-AFC2A1B1-1502-45AC-B2E0-CD50C324420EQ35605872-5C704ECF-8B47-4608-8301-E6C2F4DBEE53Q35606640-2DC6FB40-2FAE-438A-B538-9736CAE9EF09Q35870148-0B1063A8-32E6-4C28-851B-65AACC137F1BQ35921549-BE515E8E-466F-41BF-B20A-765AE2C5BA61Q36492862-5B652E8A-6729-44E4-B634-69158FA512B9Q37362586-12198F83-2C3E-4947-ACFF-A68AED490C4FQ37407248-46726641-3C7F-43B0-A31A-E323BC5D7EC8Q37531368-8C097673-0020-44A6-BCB5-AEF990580E70Q37639234-7CD99DD7-E233-4AA6-B635-DDD22782B82DQ37999072-8A2F79B7-298C-440F-9DB2-892FB2430439Q38756492-EA1D1BDE-8288-4FFC-A5B5-FC68CF3D2910Q39243402-6A2FBA83-51CB-4EC4-B2A2-1AEBEAC4B061Q39266196-08507D04-3EBB-407C-A479-CE64BBA0E43AQ39459774-7D6A3489-7D26-4E38-B26F-99CE07B5EE19Q41009749-C033A200-FED5-4C4D-96B7-87588AFB2C5EQ41286875-2E38DFEE-47D0-4E62-AB7A-1220E8E65AEDQ42465688-28D4B1C0-0BA3-422C-BE90-56E49025E0E6Q48146766-B05C5F4D-B8BE-430B-82E7-8F5509D4E430Q52709080-2AB84043-C573-4A2E-BE3B-C45B7C727832Q54188074-F8088C3C-1D27-4070-8A44-6A3A9B557FF9
P2860
Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Polycomb group protein EZH2 is ...... ive of worse clinical outcome.
@en
Polycomb group protein EZH2 is ...... ive of worse clinical outcome.
@nl
type
label
Polycomb group protein EZH2 is ...... ive of worse clinical outcome.
@en
Polycomb group protein EZH2 is ...... ive of worse clinical outcome.
@nl
prefLabel
Polycomb group protein EZH2 is ...... ive of worse clinical outcome.
@en
Polycomb group protein EZH2 is ...... ive of worse clinical outcome.
@nl
P2093
P2860
P356
P1433
P1476
Polycomb group protein EZH2 is ...... ive of worse clinical outcome.
@en
P2093
Anthony Lucci
Massimo Cristofanilli
Naoto T Ueno
Nour Sneige
Thomas A Buchholz
Vicente Valero
Xiaoping Sun
P2860
P304
P356
10.1002/CNCR.26179
P407
P577
2011-06-28T00:00:00Z